|
PL2334295T3
(pl)
|
2008-09-02 |
2017-12-29 |
Amarin Pharmaceuticals Ltd |
Kompozycja farmaceutyczna zawierająca kwas eikozapentaenowy i kwas nikotynowy oraz sposoby jej zastosowania
|
|
CA2740874C
(en)
|
2008-10-17 |
2018-02-27 |
Metabolex, Inc. |
Use of ppar.gamma.agonists to reduce small dense ldl particles
|
|
NZ720946A
(en)
|
2009-04-29 |
2017-09-29 |
Amarin Pharmaceuticals Ie Ltd |
Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
|
|
CN104856985B
(zh)
|
2009-04-29 |
2019-01-04 |
阿马里纳制药爱尔兰有限公司 |
稳定的药物组合物和使用其的方法
|
|
CA3026006C
(en)
|
2009-06-15 |
2021-09-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
|
|
WO2011038122A1
(en)
|
2009-09-23 |
2011-03-31 |
Amarin Corporation Plc |
Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
|
|
US9719068B2
(en)
|
2010-05-06 |
2017-08-01 |
Children's Hospital Medical Center |
Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
|
|
US20140127289A1
(en)
|
2010-11-29 |
2014-05-08 |
Armarin Pharmaceuticals Ireland Limited |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
|
US11712429B2
(en)
|
2010-11-29 |
2023-08-01 |
Amarin Pharmaceuticals Ireland Limited |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
|
US20130131170A1
(en)
|
2011-11-07 |
2013-05-23 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
|
US11291643B2
(en)
|
2011-11-07 |
2022-04-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
|
JP6307442B2
(ja)
|
2012-01-06 |
2018-04-04 |
アマリン ファーマシューティカルス アイルランド リミテッド |
対象の高感度（ｈｓ−ｃｒｐ）のレベルを低下させる組成物および方法
|
|
RS67161B1
(sr)
|
2012-06-29 |
2025-09-30 |
Amarin Pharmaceuticals Ie Ltd |
Etil estar eikozapentaenske kiseline za upotrebu u smanjenju rizika od nesmrtonosnog šloga kod pacijenta na terapiji statinima
|
|
WO2014074552A2
(en)
|
2012-11-06 |
2014-05-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
|
|
US20140187633A1
(en)
|
2012-12-31 |
2014-07-03 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
|
|
US9814733B2
(en)
*
|
2012-12-31 |
2017-11-14 |
A,arin Pharmaceuticals Ireland Limited |
Compositions comprising EPA and obeticholic acid and methods of use thereof
|
|
US9452151B2
(en)
|
2013-02-06 |
2016-09-27 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing apolipoprotein C-III
|
|
US9624492B2
(en)
|
2013-02-13 |
2017-04-18 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
|
|
US9662307B2
(en)
|
2013-02-19 |
2017-05-30 |
The Regents Of The University Of Colorado |
Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
|
|
US9283201B2
(en)
|
2013-03-14 |
2016-03-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating or preventing obesity in a subject in need thereof
|
|
US20140271841A1
(en)
|
2013-03-15 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
|
|
US10966968B2
(en)
|
2013-06-06 |
2021-04-06 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
|
|
US20150065572A1
(en)
|
2013-09-04 |
2015-03-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing prostate cancer
|
|
US9585859B2
(en)
|
2013-10-10 |
2017-03-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
|
|
US10272058B2
(en)
|
2014-03-20 |
2019-04-30 |
Cymabay Therapeutics, Inc. |
Treatment of intrahepatic cholestatic diseases
|
|
US9486428B2
(en)
|
2014-03-20 |
2016-11-08 |
Cymabay Therapeutics, Inc. |
Treatment of intrahepatic cholestatic diseases
|
|
NZ724740A
(en)
|
2014-04-11 |
2019-11-29 |
Cymabay Therapeutics Inc |
Treatment of nafld and nash
|
|
EP3149156B1
(en)
|
2014-05-28 |
2021-02-17 |
Children's Hospital Medical Center |
Methods and systems for converting precursor cells into gastric tissues through directed differentiation
|
|
US10561631B2
(en)
|
2014-06-11 |
2020-02-18 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing RLP-C
|
|
WO2015195662A1
(en)
|
2014-06-16 |
2015-12-23 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
|
|
EP3207123A1
(en)
|
2014-10-17 |
2017-08-23 |
Children's Hospital Center D/b/a Cincinnati Children's Hospital Medical Center |
In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
|
|
WO2016154258A1
(en)
*
|
2015-03-26 |
2016-09-29 |
T3D Therapeutics, Inc. |
Methods of treating liver disease using indane acetic acid derivatives
|
|
KR102644400B1
(ko)
|
2015-04-28 |
2024-03-06 |
바스프 에이에스 |
비알코올성 지방간염의 예방 및/또는 치료를 위한 구조적으로 강화된 함황 지방산의 용도
|
|
WO2017049157A1
(en)
*
|
2015-09-18 |
2017-03-23 |
Duke University |
Methods and compositions for the treatment of steatosis-associated disorders
|
|
WO2017139708A1
(en)
|
2016-02-10 |
2017-08-17 |
Synlogic, Inc. |
Bacteria engineered to treat nonalcoholic steatohepatitis (nash)
|
|
US10406130B2
(en)
|
2016-03-15 |
2019-09-10 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
|
US12053445B2
(en)
|
2016-03-31 |
2024-08-06 |
Genfit |
Methods of treatment of cholestatic diseases
|
|
ES2929758T3
(es)
|
2016-05-05 |
2022-12-01 |
Childrens Hospital Med Ct |
Métodos para la fabricación in vitro de tejido del fondo gástrico y composiciones relacionadas con el mismo
|
|
GB201614455D0
(en)
*
|
2016-08-24 |
2016-10-05 |
Univ Oxford Innovation Ltd |
Biomarkers
|
|
SG11201903697WA
(en)
|
2016-11-04 |
2019-05-30 |
Childrens Hospital Med Ct |
Liver organoid compositions and methods of making and using same
|
|
US10493363B2
(en)
*
|
2016-11-09 |
2019-12-03 |
Activision Publishing, Inc. |
Reality-based video game elements
|
|
KR102807995B1
(ko)
|
2016-12-05 |
2025-05-16 |
칠드런즈 호스피탈 메디칼 센터 |
결장 유사장기 및 이를 제조 및 사용하는 방법
|
|
JP7248586B2
(ja)
|
2017-04-14 |
2023-03-29 |
チルドレンズ ホスピタル メディカル センター |
複数ドナー幹細胞組成物およびそれを作製する方法
|
|
EP4234536A3
(en)
|
2017-05-05 |
2023-10-25 |
Hepanova, Inc. |
Amino-aryl-benzamide compounds and methods of use thereof
|
|
WO2018213663A1
(en)
|
2017-05-19 |
2018-11-22 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject having reduced kidney function
|
|
US10512622B2
(en)
|
2017-07-14 |
2019-12-24 |
Cymabay Therapeutics, Inc. |
Treatment of intrahepatic cholestatic diseases
|
|
US20190076500A1
(en)
|
2017-09-13 |
2019-03-14 |
Novartis Ag |
Combinations comprising fxr agonists
|
|
WO2019074793A1
(en)
|
2017-10-10 |
2019-04-18 |
Children's Hospital Medical Center |
OESOPHAGIAN TISSUE COMPOSITIONS AND / OR ORGANOIDS AND METHODS OF MAKING SAME
|
|
WO2019083070A1
(ko)
*
|
2017-10-27 |
2019-05-02 |
주식회사 삼양사 |
비알코올성 지방간 질환의 예방 또는 개선용 조성물
|
|
HRP20241643T1
(hr)
|
2017-12-06 |
2025-02-14 |
Basf As |
Derivati masnih kiselina za liječenje nealkoholnog steatohepatitisa
|
|
WO2019126626A1
(en)
|
2017-12-21 |
2019-06-27 |
Children's Hospital Medical Center |
Digitalized human organoids and methods of using same
|
|
US11058661B2
(en)
|
2018-03-02 |
2021-07-13 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
|
|
AU2019311783A1
(en)
|
2018-07-26 |
2021-02-04 |
Children's Hospital Medical Center |
Hepato-biliary-pancreatic tissues and methods of making same
|
|
JP2021535753A
(ja)
|
2018-09-12 |
2021-12-23 |
チルドレンズ ホスピタル メディカル センター |
造血幹細胞およびその派生体の生成のためのオルガノイド組成物
|
|
MA50490A
(fr)
|
2018-09-24 |
2020-09-02 |
Amarin Pharmaceuticals Ie Ltd |
Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
|
|
EP3880185A1
(en)
*
|
2018-11-16 |
2021-09-22 |
CymaBay Therapeutics, Inc. |
Combination treatment of nafld and nash
|
|
US20200155487A1
(en)
*
|
2018-11-16 |
2020-05-21 |
Cymabay Therapeutics, Inc. |
Treatment of obesity and its complications
|
|
CN111320609A
(zh)
|
2018-12-13 |
2020-06-23 |
拓臻股份有限公司 |
一种THRβ受体激动剂化合物及其制备方法和用途
|
|
CA3141814A1
(en)
|
2019-05-31 |
2020-12-03 |
Children's Hospital Medical Center |
Shaped organoid compositions and methods of making same
|
|
WO2020243613A1
(en)
|
2019-05-31 |
2020-12-03 |
Children's Hospital Medical Center |
Methods of generating and expanding hematopoietic stem cells
|
|
CN114430743A
(zh)
|
2019-08-23 |
2022-05-03 |
拓臻制药公司 |
甲状腺激素受体β激动剂化合物
|
|
AU2020346057A1
(en)
|
2019-09-12 |
2022-04-21 |
Terns Pharmaceuticals, Inc. |
Thyroid hormone receptor beta agonist compounds
|
|
BR112022009189A2
(pt)
|
2019-11-12 |
2022-07-26 |
Amarin Pharmaceuticals Ie Ltd |
Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial
|
|
WO2021097027A1
(en)
*
|
2019-11-14 |
2021-05-20 |
Cymabay Therapeutics, Inc. |
Seladelpar for use in the treatment of alcoholic liver disease
|
|
WO2021097034A1
(en)
|
2019-11-14 |
2021-05-20 |
Cymabay Therapeutics, Inc. |
Seladelpar for use in the treatment of intestinal barrier dysfunction and associated diseases
|
|
IL298144A
(en)
*
|
2020-05-13 |
2023-01-01 |
Terns Pharmaceuticals Inc |
Combination treatment of liver disorders
|
|
AU2022263358A1
(en)
|
2021-04-21 |
2023-11-30 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing the risk of heart failure
|
|
EP4337184A1
(en)
*
|
2021-05-11 |
2024-03-20 |
Genfit |
Ppar-agonists for use in the treatment of liver failure
|